The role of amyloid β in the pathogenesis of Alzheimer's disease

Postgraduate Medical Journal

Volumn 90, Issue 1060, 2014, Pages 113-117

  Gilbert, Barnabas James ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SOLANEZUMAB;

ALTERNATIVE HYPOTHESIS; ALZHEIMER DISEASE; AMNESIA; BRAIN; CLINICAL TRIAL (TOPIC); COGNITION; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; IMMUNOPRECIPITATION; LONG TERM POTENTIATION; MICROGLIA; NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOXICITY;

EID: 84892867546     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-201515rep     Document Type: Review

References (81)

1. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008;258:28-47.
2. Prince M, Bryce R, Ferri CP. World Alzheimer report 2011: the benefits of early diagnosis and intervention. Alzheimer's Disease International, 2011. http://www.alz. co.uk/research/WorldAlzheimerReport2011.pdf (accessed Feb 2013).
3. Dementia 2012: A National Challenge. Alzheimer's Society 2012. http://www. alzheimers.org.uk/dementia2012 (accessed Feb 2013).
4. Boeve BF. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat Disord 2012;18:S41-4.
5. Sá F, Pinto P, Cunha C, et al. Differences between early and late-onset Alzheimer's disease in neuropsychological tests. Front Neurol 2012;3:81.
6. Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17:1236-48.
7. Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
8. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 1998;54:77-95.
9. Mohamed A, Cortez L, de Chaves EP. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Curr Protein Pept Sci 2011;12:235-57.
10. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
11. Evin G, Weidemann A. Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. Peptides 2002;23:1285-97.
12. Cappai R, White AR. Amyloid beta. Int J Biochem Cell Biol 1999;31:885-9.
13. Sandberg A, Luheshi LM, Söllvander S, et al. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A 2010;107:15595-600.
14. Hatters DM, Griffin MD. Diagnostics for amyloid fibril formation: where to begin? Methods Mol Biol 2011;752:121-36.
15. Lomakin A, Chung DS, Benedek GB, et al. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci U S A 1996;93:1125-9.
16. McLaurin J, Yang D, Yip CM, et al. Review: modulating factors in amyloid-beta fibril formation. J Struct Biol 2000;130:259-70.
17. Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 2001;276:35176-84.
18. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
19. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012;15:349-57.
20. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003;278:34882-9.
21. Cleary JP. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.
22. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53.
23. Wang Z, Chang L, Klein WL, et al. Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem 2004;47:3329-33.
24. Lashuel HA, Lansbury PT Jr. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 2006;39:167-201.
25. Hoshi M, Sato M, Matsumoto S, et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci USA 2003;100:6370-5.
26. Cohen AS, Calkins E. Electron microscopic observation on a fibrous component in amyloid of diverse origins. Nature 1959;183:1202-3.
27. Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 1969;131:1373-5.
28. Gordon DJ, Meredith SC. Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. Biochemistry 2003;42:475-85.
29. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 1964;44:269-97.
30. Pike CJ, Burdick D, Walencewicz AJ, et al. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993;13:1676-87.
31. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250:279-82.
32. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 1994;91:12243-7.
33. Jean L, Lee CF, Lee C, et al. Competing discrete interfacial effects are critical for amyloidogenesis. FASEB J 2010;24:309-17.
34. Zhou Z, Fan JB, Zhu HL, et al. Crowded cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J Biol Chem 2009;284:30148-58.
35. Terry RD, Masliah E, Hansen LA. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry RD, Katzman R, Bick KL Alzheimer disease. 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 1999:187-206.
36. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000;20:4050-8.
37. Kawarabayashi T, Younkin LH, Saido TC, et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-81.
38. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-7.
39. Cheng IH, Scearce-Levie K, Legleiter J, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 2007;282:23818-28.
40. Gschwind M, Huber G. Apoptotic cell death induced by beta-amyloid 1-42 is cell type dependent. J Neurochem 1995;65:292-300.
41. Podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995;270:9564-70.
42. Oddo S, Caccamo A, Tran L, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006;281:1599-604.
43. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110:1129-34.
44. Buccafusco JJ. Methods of behavior analysis in neuroscience. 2nd edn. (Frontiers in Neuroscience). Boca Raton, FL: CRC Press, 2009.
45. Noraberg J. Organotypic brain slice cultures: an efficient and reliable method for neurotoxicological screening and mechanistic studies. Altern Lab Anim 2004;32:329-37.
46. Kim HJ, Chae SC, Lee DK, et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 2003;17:118-20.
47. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42.
48. Decker H, Jürgensen S, Adrover MF, et al. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem 2010;115:1520-9.
49. Hellweg R, Wirth Y, Janetzky W, et al. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J Geriatr Psychiatry 2012;27:651-6.
50. Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE 2012;7:e35185.
51. Lossi L, Alasia S, Salio C, et al. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. Prog Neurobiol 2009;88:221-45.
52. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003;100:10417-22.
53. Asaithambi A, Mukherjee S, Thakur MK. Age-dependent degradation of amyloid precursor protein in the post-mortem mouse brain cortex. Mol Biol Rep 1999;26:179-84.
54. Panda D, Goode BL, Feinstein SS, et al. Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau. Biochemistry 1995;34:11117-27.
55. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011;108:5819-24.
56. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688-92.
57. Reed MN, Hofmeister JJ, Jungbauer L, et al. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol Aging 2011;32:1784-94.
58. Jan A, Adolfsson O, Allaman I, et al. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem 2011;286:8585-96.
59. Chung H, Brazil MI, Soe TT, et al. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 1999;274:32301-8.
60. Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 2003;23:2665-74.
61. Majumdar A, Cruz D, Asamoah N, et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell 2007;18:1490-6.
62. Majumdar A, Capetillo-Zarate E, Cruz D, et al. Degradation of Alzheimer's amyloid fibrils by microglia requires delivery of CIC-7 to lysosomes. Mol Biol Cell 2011;22:1664-76.
63. Sakono M, Zako T, Ueda H, et al. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. FEBS J 2003;275:5982-93.
64. Chinopoulos C, Adam-Vizi V. Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J 2006;273:433-50.
65. Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis 2001;8:19-31.
66. Pan XD, Zhu YG, Lin N, et al. Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease. Mol Neurodegener 2011;6:45.
67. Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 2007;321:823-9.
68. Smith MA, Casadesus G, Joseph JA, et al. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002;33:1194-9.
69. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275:19439-42.
70. Bishop GM, Robinson SR. Human Abeta1-42 reduces iron-induced toxicity in rat cerebral cortex. J Neurosci Res 2003;73:316-23.
71. Kontush A. Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. Cell Mol Neurobiol 2001;21:299-315.
72. Kuperstein I, Broerson K, Benilova I, et al. Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010;29:3408-20.
73. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220-5.
74. Sierks MR, Chatterjee G, McGraw C, et al. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011;3:1188-96.
75. Ferreira LK, Busatto GF. Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo) 2011;66:19-24.
76. Verdurand M, Bort G, Tadino V, et al. Automated radiosynthesis of the Pittsburg compound-B using a commercial synthesizer. Nucl Med Commun 2008;29:920-6.
77. Kayed R, Head E, Sarsoza F, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2007;2:18.
78. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62.
79. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res 2012;43:694-8.
80. Grundman M, Dibernardo A, Raghavan N, et al. 2012: A watershed year for Alzheimer's disease research. J Nutr Health Aging 2013;17:51-3.
81. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;3:321-9.